Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May;76(5):906-913.
doi: 10.1136/annrheumdis-2016-210324. Epub 2016 Dec 7.

Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications

Michael J Ombrello  1 Victoria L Arthur  1 Elaine F Remmers  2 Anne Hinks  3 Ioanna Tachmazidou  4 Alexei A Grom  5   6 Dirk Foell  7 Alberto Martini  8   9 Marco Gattorno  9 Seza Özen  10 Sampath Prahalad  11   12 Andrew S Zeft  13 John F Bohnsack  14 Norman T Ilowite  15 Elizabeth D Mellins  16 Ricardo Russo  17 Claudio Len  18 Maria Odete E Hilario  18 Sheila Oliveira  19 Rae S M Yeung  20   21   22 Alan M Rosenberg  23 Lucy R Wedderburn  24   25 Jordi Anton  26 Johannes-Peter Haas  27 Angela Rosen-Wolff  28 Kirsten Minden  29   30 Klaus Tenbrock  31 Erkan Demirkaya  10 Joanna Cobb  3   32 Elizabeth Baskin  1 Sara Signa  8 Emily Shuldiner  1 Richard H Duerr  33   34 Jean-Paul Achkar  35   36 M Ilyas Kamboh  34 Kenneth M Kaufman  5   6 Leah C Kottyan  5   6 Dalila Pinto  37 Stephen W Scherer  38 Marta E Alarcón-Riquelme  39   40 Elisa Docampo  41   42 Xavier Estivill  42   43 Ahmet Gül  44 British Society of Pediatric and Adolescent Rheumatology (BSPAR) Study Group, Inception Cohort of Newly Diagnosed Patients with Juvenile Idiopathic Arthritis (ICON-JIA) Study Group, Childhood Arthritis Prospective Study (CAPS) Group, Randomized Placebo Phase Study of Rilonacept in sJIA (RAPPORT) Investigators, Sparks-Childhood Arthritis Response to Medication Study (CHARMS) Group, Biologically Based Outcome Predictors in JIA (BBOP) GroupCarl D Langefeld  45 Susan Thompson  5   6 Eleftheria Zeggini  4 Daniel L Kastner  2 Patricia Woo  25 Wendy Thomson  3   32
Affiliations

Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications

Michael J Ombrello et al. Ann Rheum Dis. 2017 May.

Abstract

Objectives: Juvenile idiopathic arthritis (JIA) is a heterogeneous group of conditions unified by the presence of chronic childhood arthritis without an identifiable cause. Systemic JIA (sJIA) is a rare form of JIA characterised by systemic inflammation. sJIA is distinguished from other forms of JIA by unique clinical features and treatment responses that are similar to autoinflammatory diseases. However, approximately half of children with sJIA develop destructive, long-standing arthritis that appears similar to other forms of JIA. Using genomic approaches, we sought to gain novel insights into the pathophysiology of sJIA and its relationship with other forms of JIA.

Methods: We performed a genome-wide association study of 770 children with sJIA collected in nine countries by the International Childhood Arthritis Genetics Consortium. Single nucleotide polymorphisms were tested for association with sJIA. Weighted genetic risk scores were used to compare the genetic architecture of sJIA with other JIA subtypes.

Results: The major histocompatibility complex locus and a locus on chromosome 1 each showed association with sJIA exceeding the threshold for genome-wide significance, while 23 other novel loci were suggestive of association with sJIA. Using a combination of genetic and statistical approaches, we found no evidence of shared genetic architecture between sJIA and other common JIA subtypes.

Conclusions: The lack of shared genetic risk factors between sJIA and other JIA subtypes supports the hypothesis that sJIA is a unique disease process and argues for a different classification framework. Research to improve sJIA therapy should target its unique genetics and specific pathophysiological pathways.

Keywords: Adult Onset Still's Disease; Gene Polymorphism; Juvenile Idiopathic Arthritis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: AAG: consulting fees and honoraria from Novimmune, Novartis, Roche. AM: consulting fees and honoraria from Abbvie, Boehringer, Celgene, CrescendoBio, Janssen, Meddimune, Novaris, NovoNordisk, Pfizer, Sanofi Aventis, Vertex and Servier, contributions have been received by G. Gaslini Hospital and the PRINTO network by BMS, GlaxoSmithKline, Hoffman-La Roche, Novartis, Pfizer, Sanofi Aventis, Schwarz Biosciences, Abbot, Francesco Angelini S.P.A., Sobi, and Merck Serono. MG: consulting and speaker fees from SOBI and Novartis, unrestricted grants to Eurofever from SOBI and Novartis. SP: consulting fees from Novartis. EDM: consulting fees from Novartis. LRW: speaker fees from Pfizer.

Figures

Figure 1
Figure 1
Genome-wide association results from meta-analysis of nine INCHARGE sJIA collections. The threshold of genome-wide significance (p<2.5×10−8) is shown by the blue line, while the orange line marks the level of significance suggestive of association (p<5×10−6). The top 10 sJIA-associated loci are labelled with the name of the nearest gene(s). INCHARGE, International Childhood Arthritis Genetics Consortium; MHC, major histocompatibility complex; sJIA, systemic juvenile idiopathic arthritis.
Figure 2
Figure 2
Systemic juvenile idiopathic arthritis (sJIA) susceptibility locus at chr1p36.32. A regional association plot demonstrates the association between sJIA) and single nucleotide polymorphisms (SNPs) in this region (A). The effect of the peak SNP (rs72632736) in each study population is demonstrated in the forest plot (B). The threshold of genome-wide significance (p<2.5×10−8) is marked by the black horizontal line in (A) and (C). Panel C shows the superimposition of sJIA-associated SNPs (inset box, A) with transcription factor-binding sites determined by chromatin immunoprecipitation (ChIP) sequencing from the Encyclopedia of Noncoding DNA Elements (ENCODE) project.
Figure 3
Figure 3
Comparison of the genetic architecture of systemic juvenile idiopathic arthritis (sJIA) with seronegative polyarticular and oligoarticular (polygo) JIA. Kernel density plots display the distribution of polygo-wGRS in sJIA cases and controls from the full study collection (A). p Value was calculated with the Wilcoxon rank-sum test. Receiver operator characteristic (ROC) curves with area under the curve (AUC) calculations demonstrate the performance of polygo-wGRS at predicting sJIA status in the full collection (B). Q–Q plots show the level of association of subsets of polygoJIA-associated single nucleotide polymorphisms in the sJIA population (C).

Comment in

References

    1. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet 2011;377:2138–49. 10.1016/S0140-6736(11)60244-4 - DOI - PubMed
    1. Petty RE, Southwood TR, Manners P, et al. . International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390–2. - PubMed
    1. Bannatyne GA, Wohlmann AS. Rheumatoid arthritis: It's clinical history, etiology, and pathology. Lancet 1896;147:1120–5. 10.1016/S0140-6736(01)61263-7 - DOI
    1. Still GF. On a form of chronic joint disease in children. Med Chir Trans 1897;80:47–60. 10.1177/095952879708000106 - DOI - PMC - PubMed
    1. Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol 2011;7:416–26. 10.1038/nrrheum.2011.68 - DOI - PMC - PubMed